The complement system, identified over a century ago by Jules Bordet as a heat-labile component of blood capable of lysing bacteria, remains one of the most sophisticated and powerful pillars of the innate immune response. Its name reflects its original description as a factor that "complemented" the ability of antibodies to destroy pathogens. Far from a simple antibacterial tool, the complement system is now understood as a highly regulated, multi-protein cascade that performs essential functions in homeostasis, immune surveillance, and inflammation. This intricate protease network involves more than 50 circulating and membrane-bound proteins, activating through a series of amplification steps that culminate in potent effector responses. Understanding the mechanisms of complement activation and its tight control is fundamental to grasping both resilient immune defense and the pathogenesis of numerous inflammatory and autoimmune diseases.

Architecture of the Complement System: Zymogens and Nomenclature

Complement proteins are primarily synthesized in the liver, although local production by macrophages, endothelial cells, and epithelial cells contributes significantly to tissue-specific responses. They circulate in the blood and interstitial fluids as inactive precursors, or zymogens. The nomenclature of these proteins reflects the historical order of their discovery. Classical pathway components are designated with the letter "C" followed by a number (e.g., C1, C4, C2, C3, C5). The products of proteolytic cleavage are indicated by lower-case letters: the larger fragment, which often binds to the target membrane, is designated "b" (e.g., C3b), while the smaller, soluble fragment is designated "a" (e.g., C3a). Alternative pathway components are denoted by capital letters (Factor B, Factor D, Factor H, Properdin). This system relies on a series of sequential proteolytic steps, protein-protein interactions, and conformational changes to transition from a resting state to a state of full activation.

The Three Canonical Activation Pathways: A Detailed Cascade

The complement system can be initiated through three distinct yet convergent biochemical pathways: the classical pathway, the lectin pathway, and the alternative pathway. All three converge at the central event of C3 cleavage, which drives downstream effector functions.

Classical Pathway

Initiation of the classical pathway requires the binding of the C1 complex to an activating surface. The C1 complex is composed of the recognition protein C1q and the associated serine proteases C1r and C1s. The primary activator is the binding of C1q to the Fc portion of antigen-bound IgG or IgM antibodies, providing a direct link between adaptive and innate immunity. Non-antibody activators, such as C-reactive protein (CRP), pentraxins, and directly bound polyanions, can also initiate this pathway. Upon binding, C1q undergoes a conformational change, activating C1r, which in turn cleaves and activates C1s. The active C1s then sequentially proteolyzes C4 into C4a and C4b and C2 into C2a and C2b. The larger fragments, C4b and C2a, combine on the pathogenic or activating surface to form the classical pathway C3 convertase, C4b2a.

Lectin Pathway

The lectin pathway is functionally analogous to the classical pathway but is triggered by pattern recognition molecules instead of antibodies. Mannose-binding lectin (MBL), ficolins (M-ficolin, L-ficolin, H-ficolin), and collectin-11 recognize specific carbohydrate arrays or acetylated residues that are abundantly displayed on bacterial, viral, fungal, and protozoan surfaces but are scarce on host cells. These recognition molecules are complexed with MBL-associated serine proteases (MASPs), specifically MASP-1, MASP-2, and MASP-3. Upon binding to a pathogen surface, MASP-2 autoactivates and subsequently cleaves C4 and C2, forming the same C3 convertase, C4b2a, as the classical pathway. MASP-1 is believed to play an important role in enhancing MASP-2 activation.

Alternative Pathway

The alternative pathway operates under a unique and continuous surveillance mechanism known as "tick-over." In the fluid phase, native C3 undergoes spontaneous, low-rate hydrolysis of its internal thioester bond, generating the conformationally altered form C3(H2O). Factor B binds to C3(H2O) and is cleaved by the very low abundance protease Factor D, forming the initial fluid-phase C3 convertase, C3(H2O)Bb. This convertase cleaves native C3 into C3a and C3b. Some of this C3b can attach covalently to proximal surfaces. On host cells, this deposited C3b is rapidly inactivated by regulatory proteins. However, on foreign or unprotected surfaces, C3b binds Factor B, which is again cleaved by Factor D to form the surface-bound alternative pathway C3 convertase, C3bBb. This complex is stabilized by the binding of properdin, the only known positive regulator of complement activation. The alternative pathway also serves as a powerful amplification loop for deposits of C3b generated by the classical or lectin pathways, ensuring robust complement activation once initiated.

Terminal Pathway: Formation of the Membrane Attack Complex

The cleavage of C3 by any of the C3 convertases is the point of convergence for all three activation pathways. The deposition of multiple C3b fragments on the activating surface is critical for the next step. When a C3b molecule binds to the C3 convertase (C4b2a or C3bBb), the complex changes its specificity to become a C5 convertase. The C5 convertase cleaves C5 into the potent anaphylatoxin C5a and the larger C5b fragment. C5b is unstable but remains bound to the convertase and sequentially assembles with C6, C7, and C8. The C5b-8 complex inserts into the cell membrane and serves as a receptor for multiple molecules of C9. These C9 molecules polymerize and insert into the membrane, forming a transmembrane pore known as the Membrane Attack Complex (MAC) or C5b-9. The MAC disrupts the osmotic integrity of the target cell, leading to lysis and death.

Biological Functions: The Effector Arsenal

Beyond direct cell lysis, the complement system orchestrates a wide array of inflammatory and immunological processes that are essential for host defense and tissue homeostasis.

Opsonization and Immune Clearance

The deposition of C3b and its proteolytic fragment iC3b onto the surface of a pathogen is one of the most biologically significant outcomes of complement activation. These fragments act as opsonins, labeling the foreign particle for recognition and ingestion by phagocytic cells. Phagocytes express complement receptors, such as CR1 (CD35) and CR3 (Mac-1, CD11b/CD18), which specifically bind to these opsonins. This binding enhances the efficiency of phagocytosis, an immunological process known as immune adherence. Pathogens not effectively cleared can be trapped and processed by the spleen and liver, underscoring the system's role in immune complex handling.

Anaphylatoxins and Inflammation

The small cleavage fragments C3a, C4a, and C5a are potent bioactive molecules known as anaphylatoxins. They bind to specific G-protein-coupled receptors (C3aR, C5aR1, C5aR2) on a variety of immune and non-immune cells. C5a is the most potent anaphylatoxin, acting as a powerful chemoattractant that recruits neutrophils, monocytes, macrophages, and eosinophils to the site of infection. It activates phagocytes, triggering degranulation and the generation of a respiratory burst. C5a and C3a also increase vascular permeability, stimulate smooth muscle contraction, and induce the release of histamine from mast cells, driving the clinical signs of inflammation—redness, heat, swelling, and pain.

Immunomodulation and Metabolic Clearance

The complement system serves a critical role in shaping adaptive immunity. The engagement of the complement receptor CR2 (CD21) on B cells by C3d-tagged antigens significantly lowers the threshold for B cell activation, enhancing antibody production and memory formation. Complement also plays a vital role in the innate clearance of cellular debris and apoptotic cells. Early complement components, particularly C1q, bind directly to the surface of dying cells, marking them for swift removal by phagocytes, preventing the release of pro-inflammatory intracellular contents that can drive autoimmunity.

Regulatory Mechanisms: Controlling the Cascade

Due to its immense destructive potential, the complement system must be exquisitely controlled at multiple levels to prevent self-inflicted "friendly fire" on host tissues. This is achieved by a cohort of regulatory proteins that target the cascade at various points.

Fluid-Phase Regulators

In the circulation, Factor H and C4-binding protein (C4BP) are the primary soluble regulators. Factor H competes with Factor B for binding to C3b and acts as a cofactor for the serine protease Factor I to cleave C3b into its inactive form, iC3b. It also accelerates the decay of the alternative pathway C3 convertase. C4BP performs analogous regulatory functions for the classical and lectin pathways, accelerating the decay of C4b2a and acting as a cofactor for Factor I-mediated cleavage of C4b. Factor I is a critical serine protease that degrades active C3b and C4b, but it requires the presence of cofactor proteins (like Factor H, C4BP, MCP, or CR1) to perform its function.

Membrane-Bound Regulators

Host cells are protected by several transmembrane regulators that are anchored to the cell membrane. Decay-accelerating factor (DAF, CD55) prevents the assembly of and accelerates the decay of both classical and alternative pathway C3 convertases. Membrane cofactor protein (MCP, CD46) binds to C3b and C4b that have deposited on the host cell, acting as a local cofactor for Factor I-mediated cleavage, permanently disabling the convertase. Complement receptor 1 (CR1, CD35) has both decay-accelerating and factor I cofactor activity. Finally, protectin (CD59) is a potent inhibitor of the terminal pathway, binding to C5b-8 and preventing the full unfolding and insertion of C9, thus blocking the formation of the lytic MAC on host cells.

The Duality of Complement: From Host Defense to Pathology

When tight regulation fails or when the system is chronically overactivated, complement directly contributes to a wide spectrum of human diseases. This pathophysiological role highlights the importance of understanding this system.

Autoimmune and Inflammatory Diseases

Deficiencies in classical pathway components, particularly C1q, C1r/s, C4, and C2, are among the strongest known genetic risk factors for developing Systemic Lupus Erythematosus (SLE). This paradoxical association is believed to stem from the defective clearance of apoptotic bodies and immune complexes that are normally processed by the classical pathway. Without this clearance, apoptotic material accumulates and serves as a source of self-antigens, driving loss of tolerance. In rheumatoid arthritis and inflammatory arthritis, excessive complement activation with generation of C5a and the MAC directly contributes to neutrophil infiltration and synovial tissue damage.

Renal Diseases

The kidney is particularly susceptible to complement-mediated injury due to the high volume of plasma filtration it handles. IgA nephropathy (Berger's disease) involves the deposition of IgA complexes in the mesangium, leading to local complement activation via the lectin pathway. Atypical Hemolytic Uremic Syndrome (aHUS) is a devastating thrombotic microangiopathy driven by uncontrolled activation of the alternative pathway, most commonly due to loss-of-function mutations in Factor H, Factor I, or MCP, or gain-of-function mutations in C3 or Factor B.

Degenerative Conditions

Age-related macular degeneration (AMD), a leading cause of blindness, is strongly associated with polymorphisms in the Complement Factor H gene. The variant CFH Y402H impairs the ability of Factor H to localize to the retina, leading to low-grade chronic complement activation and inflammation that drives the progressive destruction of the retinal pigment epithelium. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by a somatic mutation in the PIGA gene, leading to the absence of GPI-anchored regulatory proteins DAF and CD59 on the surface of red blood cells, rendering them exquisitely sensitive to lysis by the MAC.

Therapeutic Targeting: The Complement Inhibitor Revolution

The growing appreciation of complement's role in severe human diseases has driven the development of a new generation of targeted therapeutics that precisely block specific steps in the cascade.

C5 Inhibitors

The clinical success of the humanized monoclonal antibody eculizumab (Soliris) and its long-acting successor ravulizumab (Ultomiris) has validated the complement system as a druggable target. These drugs bind with high affinity to C5, preventing its cleavage by the C5 convertase and thus blocking the generation of both the potent anaphylatoxin C5a and the lytic MAC. They are approved life-saving therapies for PNH, aHUS, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder.

Upstream and Alternative Pathway Inhibitors

Despite the effectiveness of C5 inhibition, some patients experience breakthrough hemolysis due to downstream C3 activation. This has driven interest in targeting the pathway further upstream. Pegcetacoplan (Empaveli) is a pegylated peptide that binds to C3 and C3b, blocking all C3 cleavage and effectively controlling both PNH and C3 glomerulopathy. Highly selective oral inhibitors targeting Factor B (iptacopan) and Factor D are currently in advanced clinical trials for a range of indications, including PNH, aHUS, and glomerular diseases, offering potential monotherapies with improved patient convenience.

Future Directions

Research continues into inhibitors of the lectin pathway (MASP-2 inhibition with narsoplimab for the prophylaxis of thrombotic microangiopathy and treatment of IgA nephropathy) and anaphylatoxin receptors (C5aR antagonists for inflammatory diseases). The ability to precisely modulate the complement system, preserving its critical host defense functions while mitigating its pathological effects, remains the ultimate goal of this exciting field.

Since its discovery over a century ago, the complement system has evolved in our understanding from a simple bactericidal serum component to a sophisticated, multi-branched network that governs tissue homeostasis, shapes adaptive immunity, and drives inflammation. The ongoing translation of complement biology into targeted, effective therapies continues to transform the treatment landscape for a growing number of rare and common diseases.